Добро пожаловать
Нажатие «Авторизоваться» означает, что вы соглашаетесь с Условия использования и политика конфиденциальности Cointime.
Зарегистрировать аккаунт
Аккаунт уже существует?
Нажатие «page.Sign up» означает, что вы соглашаетесь с <a class="underline" href="#term-of-service">Условия использования</a> и a class="underline" href="#privacy-policy">политика конфиденциальности</a> Cointime.
Войдите, используя email
Зарегистрируйтесь с помощью email
твой почтовый ящик
Проверь свои входящие
Нажмите на ссылку в , чтобы войти.
Нажмите на ссылку в , чтобы зарегистрироваться.
Eradivir
company
About
Eradivir is a biotech company that aims to develop a non-immunological targeting agent for use against the virus that causes COVID-19.
- 1 - 10
Details
- Last Funding Type
- Grant
- Last Funding Money Raised
- $256K
- Industries
- Biotechnology,Health Care,Therapeutics
- Founded date
- Jan 1, 2020
- Number Of Employee
- 1 - 10
- Operating Status
- Active
Eradivir is a biotech company that aims to develop a non-immunological targeting agent for use against the virus that causes COVID-19. The company was founded in 2020 and is headquartered in West Lafayette, Indiana.
Funding Rounds
Number of Funding Rounds
Total Funding Amount
1
$256K
Eradivir has raised a total of
$256K
in funding over 2 rounds. Their latest funding was raised on
Feb 5, 2021 from a Grant round.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Feb 5, 2021 | Grant | $256K | 1 |
National Science Foundation
|
— | Detail |
Investors
Number of Lead Investors
Number of Investors
1
1
Eradivir is funded by 1 investors.
National Science Foundation
are the most recent investors.
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
National Science Foundation
|
Yes | Grant |
Share
Twitter
LinkedIn
Line
Facebook
Telegram
Email
Page Link
